GLP-1 RAs Provide Greater Hepatic Benefit Than SGLT2is For MASLD, Type 2 Diabetes
The Evolving Landscape of Liver Disease Treatment: GLP-1 Receptor Agonists vs. SGLT2 Inhibitors Recent studies have spotlighted the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over sodium-glucose cotransporter-2 inhibitors (SGLT2i) in managing liver conditions associated with type 2 diabetes (T2D). This breakthrough has potential ramifications for the future of liver disease treatment, particularly for … Read more